Richard Lock Selected Research

Richard Lock Research Topics

Disease

42	Neoplasms (Cancer) 01/2017 - 01/2007
10	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2017 - 04/2006
10	Leukemia 08/2013 - 04/2006
7	Neuroblastoma 01/2017 - 06/2008
5	Glioblastoma (Glioblastoma Multiforme) 01/2014 - 06/2008
5	Osteosarcoma (Osteogenic Sarcoma) 12/2012 - 06/2008
5	Rhabdomyosarcoma 08/2012 - 06/2008
4	Ewing Sarcoma (Sarcoma, Ewing) 04/2011 - 06/2008
3	Hypoxia (Hypoxemia) 08/2012 - 01/2011
3	Rhabdoid Tumor (Rhabdoid Tumors) 12/2009 - 06/2008
2	Wilms Tumor (Wilm's Tumor) 08/2012 - 12/2009
1	COVID-19 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Carcinogenesis 01/2013
1	Myeloid Leukemia (Leukemia, Myelocytic) 10/2012
1	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 08/2012
1	Lymphoma (Lymphomas) 04/2012
1	Inflammation (Inflammations) 10/2011
1	Hyperalgesia 10/2011
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 06/2011
1	Astrocytoma (Pilocytic Astrocytoma) 10/2010
1	Breast Neoplasms (Breast Cancer) 10/2009
1	Alveolar Rhabdomyosarcoma 07/2008
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2008
1	Carcinoma (Carcinomatosis) 06/2008

Drug/Important Bio-Agent (IBA)

22	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 01/2017 - 12/2007
4	Proteins (Proteins, Gene)FDA Link 01/2013 - 04/2006
2	Vincristine (Oncovin)FDA LinkGeneric 08/2013 - 12/2007
2	Transcription Factors (Transcription Factor)IBA 01/2013 - 06/2011
2	Messenger RNA (mRNA)IBA 02/2012 - 04/2006
2	ProdrugsIBA 09/2011 - 01/2011
2	PR-104IBA 09/2011 - 01/2011
2	Pharmaceutical PreparationsIBA 07/2008 - 01/2007
1	Anesthetics (Anesthetic Agents)IBA 01/2020
1	CBLC137IBA 01/2017
1	selinexorIBA 02/2016
1	Exportin 1 ProteinIBA 02/2016
1	Caspase 8 (Caspase-8)IBA 01/2016
1	Inhibitor of Apoptosis ProteinsIBA 01/2016
1	birinapantIBA 01/2016
1	CaspasesIBA 01/2016
1	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acidIBA 01/2016
1	talazoparibIBA 01/2015
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2015
1	sapanisertibIBA 08/2014
1	quisinostatIBA 02/2014
1	Polo-Like Kinase 1IBA 01/2014
1	BI 6727IBA 01/2014
1	eribulin FDA Link 08/2013
1	Antimitotic AgentsIBA 08/2013
1	DNA (Deoxyribonucleic Acid)IBA 05/2013
1	XL147IBA 05/2013
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 05/2013
1	Temozolomide (Temodar)FDA LinkGeneric 05/2013
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2013
1	dinaciclibIBA 12/2012
1	SGI 1776IBA 10/2012
1	MK 2206IBA 09/2012
1	JNJ 26854165IBA 08/2012
1	pevonedistatIBA 08/2012
1	Everolimus FDA Link 08/2012
1	Glucose (Dextrose)FDA LinkGeneric 08/2012
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 07/2012
1	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 05/2012
1	LCL161IBA 04/2012
1	Mechanistic Target of Rapamycin Complex 2IBA 02/2012
1	Mechanistic Target of Rapamycin Complex 1IBA 02/2012
1	Topotecan (Hycamtin)FDA LinkGeneric 02/2012
1	Genz-644282IBA 02/2012
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 02/2012
1	Lenalidomide (CC 5013)FDA Link 10/2011
1	Aldo-Keto ReductasesIBA 09/2011
1	PR-104AIBA 09/2011
1	Oxidoreductases (Dehydrogenase)IBA 09/2011
1	Aldo-Keto Reductase Family 1 Member C3IBA 09/2011
1	PolyaminesIBA 08/2011
1	SpermineIBA 08/2011
1	BMS 754807IBA 04/2011
1	Phosphotransferases (Kinase)IBA 12/2010
1	Sorafenib (BAY 43-9006)FDA Link 12/2010
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2010
1	AZD 6244IBA 10/2010
1	MLN 8237IBA 07/2010
1	mapatumumabIBA 02/2010
1	ispinesibIBA 12/2009
1	Tyrosine Kinase InhibitorsIBA 10/2009
1	Lapatinib (GW572016)FDA Link 10/2009
1	plitidepsin (aplidine)IBA 09/2009
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 07/2008
1	Sunitinib (Sutent)FDA Link 07/2008
1	Antineoplastic Agents (Antineoplastics)IBA 07/2008
1	robatumumabIBA 06/2008
1	ABT-737IBA 06/2008
1	navitoclaxIBA 06/2008
1	Insulin-Like PeptidesIBA 06/2008

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2016 - 08/2012
2	Therapeutics 08/2013 - 01/2011
2	Withholding Treatment 07/2008 - 06/2008
1	Radiotherapy 05/2013
1	Duration of Therapy 07/2010